Is degree of chronic illness management in heart transplant centers associated with better patient survival? Findings from the intercontinental BRIGHT study

Maan Isabella Cajita1, Kris Denhaerynck2, Lut Berben2, Fabienne Dobbels2,3, Johan Van Cleemput4, Maria Crespo-Leiro5, Jan Van Keer6, Alain Jean Poncelet7, Cynthia Russell8 and Sabina De Geest2,3,#

1College of Nursing, University of Illinois at Chicago, Chicago, IL, USA
2Department Public Health, Institute of Nursing Science, University of Basel, Switzerland
3Department of Public Health and Primary Care, Academic Center for Nursing and Midwifery, KU Leuven, Belgium
4Heart Transplant Program, University Hospital of Leuven, Faculty of Medicine, KU Leuven, Leuven, Belgium
5Complexo Hospitalario Universitario A Coruña (CHUAC), CIBERCV, INIBIC, Universidade da Coruña (UDC), La Coruña, Spain
6Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
7Cliniques Universitaires Saint-Luc, Brussels, Belgium
8School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO, USA
#on behalf of the BRIGHT Study Team.

Corresponding author:
Sabina De Geest, Department Public Health, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, CH-4056 Basel, Switzerland.
Email: sabina.degeest@unibas.ch

© The Author(s) 2021
DOI: 10.1177/17423953211039773
journals.sagepub.com/home/chi
Abstract

Purpose: To explore the association between the degree of Chronic illness management and survival rates at 1-, 3-, 5-years post heart transplantation.

Methods: Exploratory secondary analysis of a cross-sectional, international study (Building Research Initiative Group study). Latent profile analysis was performed to classify 36 heart transplant centers according to the degree of chronic illness management.

Results: The analysis resulted in 2 classes with 29 centers classified as “low-degree chronic illness management” and 7 centers as “high-degree chronic illness management”. After 1-year posttransplantation, the high-degree chronic illness management class had a significantly greater mean survival rate compared to the low-degree chronic illness management class (88.4% vs 84.2%, \( p = 0.045 \)) and the difference had a medium effect size (\( \eta^2 = .06 \)). No difference in survival for the other time points was observed. Patients in high-degree chronic illness management centers had 52% lower odds of moderate to severe drinking (95% confidence interval .30–.78, \( p = 0.003 \)). No significant associations between degree of chronic illness management and the other recommended health behaviors were observed.

Conclusions: The findings from this exploratory study offer preliminary insight into a system-level pathway (chronic illness management) for improving outcomes for heart transplant recipients. The signals observed in our data support further investigation into the effectiveness of chronic illness management-based interventions in heart transplant follow-up care.

Keywords
Chronic illness management, heart transplant, survival, patient outcomes, latent profile analysis

Introduction

Despite the significant improvement in physical function and quality of life posttransplantation, heart transplant (HTx) recipients are still considered to have a chronic condition since they have to adhere to a life-long complex therapeutic regimen and regular medical follow-up to monitor graft function and prevent or treat co-morbidities. Given the multifaceted nature of the post-transplant regimen and the impact of behavioral and psychosocial factors on HTx

Javier Segovia-Cubero (Hospital Puerta de Hierro, Madrid, Spain); Luis Almenar-Bonet (Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain); Carmen Segura Saint-Gerons (Hospital Univeritario Reina Sofia, Córdoba, Spain); Paul Mohacsi (University Hospital of Bern, Bern, Switzerland); Eva Horvath & Stalder-Ochsner Irene (University Hospital Zurich, Zurich, Switzerland); Cheryl Riotto (Papworth Hospital, Cambridge, UK); Gareth Parry (Freeman Hospital, Newcastle, UK); Ashi Firouzi (Royal Brompton & Harefield NHS Foundation Trust, London, UK); Stella Kozuszko (Toronto General Hospital, Toronto, Canada); Haissam Haddad (University of Ottawa Heart Institute, Ottawa, ON, Canada); Annemarie Kaaan (St Paul’s Hospital, Vancouver, BC, Canada); Grant Fisher (London Health Sciences Center, London, ON, Canada); Tara Miller (Duke University Hospital, Durham, NC, USA); Maureen Flattery (Virginia Commonwealth University Health System, Richmond, VA, USA); Kristin Ludrosky/Nancy Albert (Cleveland Clinic, OH, USA); Bernice Coleman (Cedars-Sinai Medical Center, Los Angeles, CA, USA); Jacqueline Trammell & Flavio Epstein (Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA, USA); Katherine St Clair, Andrew Kao (St Luke’s Hospital, Kansas City, MO, USA); Maria Molina (Hospital of the University of Pennsylvania, Philadelphia, PA, USA); Karyn Ryan Canales (Ochsner Medical Center, New Orleans, LA, USA); Samira Scaldo de Almeida (Hospital Israelita Albert Einstein, São Paulo & Hospital Municipal Vila Santa Catarina - Ministerio da Saude PROAD/SUS, São Paulo, Brazil); Bartira de Aguiar Roza, Paulista School of Nursing, Federal University of Sao Paulo, Sao Paulo, Brazil; Andrea Cotait Ayoub (Instituto Dante Pasanese de Cardiologia, São Paulo, Brazil); Fernanda Barone (Instituto de Coração da Universidade de São Paulo, São Paulo Brazil); Michelle Harkess (St Vincent’s Hospital, Sydney, Australia); Joanne Maddicks-Law (The Prince Charles Hospital, Brisbane, Australia).
outcomes, HTx recipients would greatly benefit from a comprehensive follow-up care that not only addresses biomedical parameters but psychosocial and behavioral functioning as well.

Chronic illness management (CIM) is an innovative approach to transplant follow-up care that could improve the health outcomes of HTx recipients. Unlike the prevailing acute care model, wherein the patient initiates the search for care in response to an acute exacerbation of a current condition or the emergence of a new condition, CIM takes a more proactive approach by ensuring continuity of care, preventive measures, and providing the patient with adequate self-management support throughout his/her long-term illness trajectory. The Innovative Care for Chronic Conditions (ICCC) framework provides a roadmap for health system re-engineering to make it more conducive to the needs of patients with chronic conditions. Under the ICCC framework, healthcare systems are encouraged to (1) promote continuity of care and care coordination; (2) improve quality through leadership and incentives; (3) organize and equip healthcare teams; (4) utilize information systems; and (5) support disease self-management and prevention. Changes in this direction would make healthcare systems better equipped to care for individuals with chronic conditions, who require long-term integrated care and support, such as HTx recipients.

Integrated care—defined as health services delivered throughout the health continuum and coordinated across different levels and sites of care—when based on principles of CIM has resulted in improved outcomes in other chronically ill populations. Among people with multiple chronic conditions, comprehensive care based on CIM principles has been shown to improve health behaviors, decrease healthcare utilization and healthcare costs. In HTx, variability in degrees of CIM among centers has been observed, yet the association between CIM and clinical outcomes have not yet been explored.

Therefore, the primary aim is to explore the association between the degree of CIM and survival rates at 1-, 3-, 5-years post HTx at the center-level. Additionally, the associations between the degree of CIM and more proximal outcomes (i.e. patients’ adherence to recommended health behaviors) will be explored.

Methods
This is a secondary analysis of the Building Research Initiative Group: CIM and Adherence in Transplantation (BRIGHT) study, a cross-sectional study that examined the multi-level factors associated with immunosuppressant non-adherence in adult HTx recipients from 36 HTx centers in 11 countries across 4 continents. Information on the methodology of the BRIGHT study has been previously published. Data were collected between March 2012 and October 2015.

Sampling strategy
The BRIGHT study used a multi-staged sampling approach. A convenience sample of countries and HTx centers were recruited, followed by a random sample of clinicians and patients using a sampling strategy guided by the size of the HTx centers. Centers that performed 50-74 HTx in 5 years were classified as small, centers performing 75–100 HTx as medium, and those performing >100 HTx as large. The size classification of the HTx centers was determined using the variability in the number of HTx performed by the participating centers and the International Society of Heart and Lung Transplantation (ISHLT) criteria. Twenty-five patients were randomly recruited from small HTx centers, 40 from medium centers, and 60 from large centers. If the center had ≤5 eligible clinicians, all were recruited. In centers with >5 eligible clinicians, a random sample of 5 clinicians was recruited.

Inclusion criteria
Countries. To be included, a country needed to have at least two eligible HTx centers.
HTx Centers. A center was eligible to participate if ≥50 HTx had been performed during the 1–5 years prior to study enrollment.

Clinicians. To be eligible, clinicians had to meet the following criteria: (1) working in the center for >6 months; (2) being employed in direct clinical practice ≥50%; and (3) being familiar with the post-transplant outpatient care at the center (e.g. physicians, nurses, transplant coordinators).

HTx Patients. HTx recipients had to meet the following criteria in order to be eligible: (1) ≥18 years of age at the time of inclusion; (2) first transplant; (3) single-organ transplant; (4) transplanted and followed up for routine care in a participating HTx center; (5) between 1 and 5 years post-transplant; and (6) able to read, understand, and sign an informed consent in the language of the participating HTx center. Patients were excluded if they were currently receiving professional support in taking their medications or if they participated in a clinical trial during the past 6 months.

Variables and measures

Degree of CIM. The degree of CIM was assessed from two perspectives (patients’ and clinicians’) to obtain a more accurate picture of the CIM practices of each HTx center. The validated short version of the Patient Assessment of Chronic Illness Care (PACIC) was used to measure the extent to which the CIM provided is congruent with the chronic care model from the patient’s perspective (Cronbach’s alpha = 0.955; test-retest reliability (r) = 0.638).15,16 The short self-report version consists of 11 items and uses a 5-point Likert scale from “almost never” to “almost always”. The summary score ranges from 11 to 55 with higher scores indicating a higher degree of CIM. For this study, the patients’ PACIC scores were averaged per center, generating a CIM score per center as perceived by patients being followed up within a given center.

The Chronic Illness Management Implementation-Building Research Initiative Group: CIM and Adherence in Transplantation (CIMI-BRIGHT) instrument was used to assess CIM implemented in the HTx centers from the clinicians’ perspectives.17 The CIMI-BRIGHT consists of 52 items and uses a 4-point Likert scale from “strongly disagree = 1” to “strongly agree = 4”.17 The CIMI-BRIGHT allows for a “don’t know” response (coded as “5”); therefore, the “don’t know” responses were treated as missing and the CIMI-BRIGHT scores were averaged per clinician. The clinicians’ CIMI-BRIGHT scores were then averaged per center with higher scores corresponding to a higher degree of CIM implemented.

Behavioral factors. Behavioral factors were analyzed at the patient level. Immunosuppressant adherence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS).18,19 Any deviation in taking, dosing, or timing was considered nonadherence.18 Adherence to other medications, including the different implementation dimensions (i.e. dosing, timing),20,21 was assessed using an adapted version of the BAASIS. The level of physical activity was measured using the Brief Physical Activity Assessment Tool.22 Patients were deemed adherent if they engaged in 20 min of vigorous physical activity ≥3 times/week or 30 min of moderate physical activity ≥5 times/week or 5 or more sessions of any combination of moderate and vigorous-intensity physical activity.22 Dietary adherence was measured by asking the patients if they were advised to follow a specific diet in the past year and, if so, how strictly they followed the recommended diet (never/rarely/sometimes/ often/ always). The subsample of patients, who were recommended a specific diet, were then classified as adherent if they followed their recommended diets often/always. Patients who were current smokers were classified as non-adherent, and patients who never smoked or quit were
considered adherent. Patients who were non-drinkers or mild drinkers (i.e. <1 drink/day for females and <2 drinks/day for males) were classified as adherent and were classified as non-adherent if they were moderate or heavy drinkers. Finally, patients who used sun protection (wear a hat, use sunscreen, stay in the shadows, or limit sun exposure often or all the time) were classified as adherent and those who did not as non-adherent. A detailed description of the measures used is published elsewhere.11

Survival rates. An investigator-developed, self-report questionnaire completed by the center’s director asked for center-level survival data and mortality risk factors that pertained to all patients at the center and not exclusively for those participating in BRIGHT. Survival rates were requested at 1, 3, and 5 years post-transplantation, congruent with the inclusion criterion (i.e. patient included were 1 till 5 years post-transplant). We assessed specific risk factors of HTx mortality: i.e. the percentage of patients: hospitalized at the time of HTx, with infection requiring IV drug therapy, with defibrillator prior to HTx, on ventilator at time of HTx, on extracorporeal membrane oxygenation (ECMO) at time of HTx, with intra-aortic balloon pump at time of HTx, or on ventricular assist device (VAD) at HTx, etiology of heart failure, and recipient gender/donor gender.

Ethical considerations

Each BRIGHT study HTx center obtained ethical approval from their institutional review board and/or national ethics committee. Written informed consent was obtained from the participating HTx recipients. Finally, completed questionnaires were coded by the HTx center and returned to the investigators in sealed envelopes to maintain confidentiality.

Statistical analyses

For this secondary analysis, data were analyzed at the center-level (i.e. PACIC and CIMI-BRIGHT scores were averaged by HTx center), except in the analysis of the associations between degree of CIM and recommended health behaviors that used patient-level data (n = 1397 patients). Analysis was performed using Stata/SE 15.

Based on the current state of science, we used the most appropriate and innovative method to classify the HTx centers. Latent profile analysis (LPA) is a measurement model in which individuals, or in this case centers, are classified into mutually exclusive and exhaustive groups based on how they perform on a set of continuous indicator variables. The 2-step LPA procedure suggested by K.E. Masyn23,24 was performed to classify the HTx centers into groups based on their degree of CIM (mean PACIC and CIMI-BRIGHT scores). The 2-step approach comprised of (1) identifying latent groups using observed indicator variables (PACIC and CIMI-BRIGHT scores); and (2) assigning centers to groups based on predicted posterior class probabilities.23 Models with two to four groups were estimated and compared based on goodness-of-fit indices and interpretability. The goodness-of-fit indices evaluated comprised of the Bayesian information criterion (BIC) and Akaike information criterion (AIC), wherein lower values correspond to better model fit.23

Sensitivity analysis was performed by using the median PACIC and CIMI-BRIGHT scores as the cutoff to classify the centers into two groups (high-/low-degree of CIM), which resulted in similar findings.

Fisher’s exact test was used to compare the center characteristics and HTx mortality risk factors between the two groups identified by the LPA. Meanwhile, logistic regression was used to compare the patients’ adherence to recommended health behaviors between the two CIM groups. Lastly, the mean survival rates at 1-, 3-, and 5 years between the two groups were compared using a random-intercepts regression analysis and partial eta-squared (\( \eta^2 \)) were calculated to determine effect sizes.
Results

Characteristics of the 36 HTx centers and their respective mean degrees of CIM are presented in Table 1. Over half ($n = 19, 52.8\%$) of the centers were located in Europe, $12 (33.3\%)$ were located in North America, $3 (8.3\%)$ in South America, and $2 (5.6\%)$ in Australia. Twenty-three ($63.9\%)$ were large centers (i.e. $>100$ HTx performed/5 years). Thirty-two ($88.9\%)$ of the HTx centers were located in urban areas and the majority ($83.3\%)$ were university teaching hospitals. The degree of CIM varied across countries. The overall mean PACIC score was $37.9 \pm 4.7$ (range: $30.9–42.0$) and the overall mean CIMI-BRIGHT score was $2.9 \pm 0.3$ (range: $2.7–3.1$).

Based on the 2-step LPA, the 2-group model had the best fit (lowest BIC and AIC values). Using the 2-group model, 29 HTx centers were classified under groups 1 and 7 in group 2. After checking the mean degree of CIM for each group, group 1 was labeled as “low-degree CIM” and group 2 as “high-degree CIM”. The mean PACIC score for group 1 was $36.9 \pm 4.1$ and $42.0 \pm 4.8$ for group 2. The mean CIMI-BRIGHT score for group 1 was $2.8 \pm 2$ and $3.3 \pm 2$ for group 2. There were no significant differences between the groups in terms of center characteristics (i.e. size, location, type), center-level mortality risk factors, etiology of heart failure, and recipient gender/donor gender, except for the percentage of patients with idiopathic ($p = 0.034$), congenital ($p = 0.013$), and other etiology of heart failure ($p = 0.026$). A comparison of the center-level characteristics between the two groups is presented in Table 2.

Figure 1 shows the comparison of the survival rates between the low-degree CIM group and the high-degree CIM group. Information on survival rates for adult HTx performed between 2010 and 2017 from the ISHLT registry is also included for reference. Not every HTx center provided information on their survival rate. At year 1, only 31 centers had available information on their survival rates. At years 3 and 5, only 29 and 30 HTx centers, respectively, had available survival rates. It should be noted that all 7 high-degree CIM centers provided information on their survival rates for years 1, 3, and 5; hence, the missing survival rates were all from low-degree CIM centers. At year 1, being in a high-degree CIM center was associated with a $4.8\%$ higher survival rate (95% confidence interval (CI) $0.11–9.4$, $p = 0.045$) and the difference had a medium effect size ($\eta^2 = 0.06$). There were no significant differences in survival rates at years 3 ($\eta^2 = 0.01$) and 5 ($\eta^2 < 0.0001$).

Patients in high-degree CIM centers had 9% higher odds of adhering to their immunosuppressants (95% CI $0.83–1.43$, $p = 0.54$) and 8% higher odds of adhering to their other medications (95% CI $0.76–1.55$, $p = 0.66$) compared to patients in low-degree CIM centers. Similarly, patients in high-degree CIM centers had 33% higher odds of engaging in sufficient physical activity (95% CI $0.94–1.90$, $p = 0.11$), 34% lower odds of smoking (95%CI $0.29–1.49$, $p = 0.32$), and 52% significantly lower odds of moderate to severe drinking (95%CI $0.30–0.78$, $p = 0.003$). Conversely, patients in high-degree CIM centers had 21% lower odds of using sun protection (95%CI $0.54–1.13$, $p = 0.20$). Lastly, patients in high-degree CIM centers had 49% significantly higher odds of being recommended a specific diet (95%CI $1.13–1.96$, $p = 0.004$). However, in the subsample of 450 patients who received diet recommendations, patients from high-degree CIM centers had 21% lower odds of adhering to diet recommendations (95%CI $0.51–1.22$, $p = 0.29$).

Discussion

The findings from this exploratory study offer preliminary insight into the potential of CIM, as a system-level pathway, in improving short-term survival for HTx recipients. HTx centers with higher degrees of CIM had a better survival rate in year 1 compared to centers with lower degrees of CIM. However, our findings do not support an association between degree
| Centers, n (%) | Europe | North America | South America | Australia |
|---------------|--------|--------------|---------------|-----------|
| Overall N = 36 |        |              |               |           |
| Belgium n = 2 |        |              |               |           |
| France n = 3  |        |              |               |           |
| Germany n = 2 |        |              |               |           |
| Italy n = 2   |        |              |               |           |
| Spain n = 5   |        |              |               |           |
| Switzerland n = 2 |    |              |               |           |
| UK n = 3      |        |              |               |           |
| Canada n = 4  |        |              |               |           |
| USA n = 8     |        |              |               |           |
| Brazil n = 3  |        |              |               |           |
| Australia n = 2 |      |              |               |           |

| Size          | Europe | North America | South America | Australia |
|---------------|--------|--------------|---------------|-----------|
| Large         | 23 (63.9) | 1 (50) | 3 (100) | 1 (50) | 2 (100) | 4 (80) | 0 | 2 (66.7) | 2 (50) | 6 (75) | 1 (33.3) | 1 (50) |
| Medium        | 8 (22.2) | 1 (50) | 0  | 1 (50) | 0 | 1 (20) | 0 | 1 (33.3) | 1 (25) | 2 (25) | 1 (33.3) | 0 |
| Small         | 5 (13.9) | 0 | 0  | 0 | 0 | 2 (100) | 0 | 1 (25) | 0 | 1 (33.3) | 1 (50) |

| Location      | Europe | North America | South America | Australia |
|---------------|--------|--------------|---------------|-----------|
| Urban         | 32 (88.9) | 1 (50) | 3 (100) | 2 (100) | 2 (100) | 5 (100) | 2 (100) | 1 (33.3) | 4 (100) | 7 (87.5) | 3 (100) | 2 (100) |
| Suburban      | 3 (8.3) | 1 (50) | 0  | 0 | 0 | 0 | 0 | 1 (33.3) | 0 | 1 (12.5) | 0 | 0 |
| Rural         | 1 (2.8) | 0 | 0  | 0 | 0 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 |

| Center type   | Europe | North America | South America | Australia |
|---------------|--------|--------------|---------------|-----------|
| University    | 30 (83.3) | 2 (100) | 3 (100) | 2 (100) | 2 (100) | 5 (100) | 2 (100) | 3 (100) | 4 (100) | 5 (62.5) | 0 | 2 (100) |
| Community     | 4 (11.1) | 0 | 0  | 0 | 0 | 0 | 0 | 0 | 2 (25) | 2 (66.7) | 0 |
| Other         | 2 (5.6) | 0 | 0  | 0 | 0 | 0 | 0 | 0 | 1 (12.5) | 1 (33.3) | 0 |

| PACIC         | Europe | North America | South America | Australia |
|---------------|--------|--------------|---------------|-----------|
| Overall       | 37.9 ± 4.7 | 38.0 ± 3.1 | 34.6 ± 2.5 | 37.9 ± 4.7 | 41.6 ± 5.1 | 40.2 ± 2.7 | 30.9 ± 5.1 | 35.1 ± 4.7 | 42 ± 5.1 | 35.8 ± 4.4 | 34.7 ± 4.7 |
| **CIMI-BRIGHT** | 2.9 ± 3 | 3.1 ± 2 | 2.8 ± 1 | 2.7 ± 4 | 2.8 ± 3 | 2.8 ± 1 | 3.0 ± 5 | 2.9 ± 2 | 3.1 ± 3 | 3.0 ± 6 | 2.7 ± 1 |

Note: $\eta^2$ were calculated to determine effect sizes. The third bar represents the survival rates for adult heart transplants performed between 2010 and 2017 (N = 31,938).\(^{22}\) PACIC scores range from 11 to 55 with higher scores indicating higher level of CMI. Mean CIMI-BRIGHT scores range from 1 to 4 with higher scores corresponding to higher level of CMI.

PACIC: Patient Assessment of Chronic Illness Care; CIMI-BRIGHT: Chronic Illness Management Implementation-Building Research Initiative Group; CMI: Chronic Illness Management.
of CIM and longer-term survival at 3- and 5-years post transplant. The cross-sectional design of the BRIGHT study meant that the degree of CIM was measured at only one time-point, making it difficult to ascertain the HTx centers’ degrees of CIM at the different time points. It is possible that the centers with high-degree CIM had only recently implemented CIM practices, which could help explain the lack of associations in the later timepoints.
Similarly, when looking into more proximal outcomes—specifically adherence to recommended health behaviors—despite the trend toward better adherence there was a lack of statistically significant associations. Given that CIM is a system-level factor, its association with health behaviors could be indirect in nature through more person-level factors, such as self-efficacy and/or patient activation, which are widely known to impact behavior change.\(^{26,27}\) At an intuitive level, it is logical to expect that the proactive, holistic support provided by a multidisciplinary team of healthcare professionals—the crux of CIM—would increase the patient’s confidence, knowledge, and skills in performing recommended health behaviors. Unfortunately, given the secondary nature of this analysis, the associations between CIM and person-level behavioral factors could not be explored.

Previous studies on renal transplant recipients provide proof of concept that re-engineering transplant follow-up care using CIM principles could be a promising solution to improving long-term transplant outcomes. Bissonnette and colleagues showed that transplant follow-up care based on CIM principles was effective in helping transplant recipients achieve targeted clinical outcomes.\(^{28}\) Meanwhile, in a randomized-controlled trial, Schmid et al. showed that a teledemically supported CIM intervention resulted in better adherence to immunosuppressants, fewer hospitalizations, and shorter lengths of hospital stay.\(^{29}\)

Admittedly, designing a CIM intervention will require adapted methods beyond the traditional clinical research methods to achieve successful implementation, adoption, and sustainability of an innovative model of care for follow-up of transplant patients.\(^{30}\) Implementation science could offer a way forward to achieve success in this regard.\(^{31}\) We are currently investing in developing, implementing, and testing this CIM-based eHealth-powered integrated care model—consisting of a human-component (i.e. care coordinator) as well as technology factors (i.e. SMILE app)—using the principles of user-centered design, agile software development, as well as implementation science to improve outcomes in stem cell transplant patients.\(^{32}\)

This model, should it prove to be successfully implemented in variable contexts and should it prove to be effective in improving clinical outcomes as well, could provide a blue print for solid organ transplantation to reengineer follow-up care based on principles of CIM.

Findings from the present exploratory study should be interpreted within the
context of its limitations. First, the cross-sectional design precludes causal inferences. Second, this secondary analysis had a small sample size (center-level), which means it could have been underpowered to detect differences in survival rates. Similarly, we could not rule out the potential impact of survival bias. Moreover, the small sample size (center-level) prevented us from controlling for potential confounders in our analyses as mentioned before. Nonetheless, potential confounders were analyzed descriptively to provide context to our findings. Lastly, the primary outcome (survival rates) was measured using self-report which could limit the validity of our findings. On the other hand, a strength of this study is the assessment of CIM from two independent perspectives (patients and clinicians), and the use of these two measures in the analysis.

Conclusion

Significant association between degree of CIM and short-term survival hints at the potential impact of CIM. The signals observed in our data—combined with the emerging evidence from intervention studies supporting the effectiveness of the CIM approach in renal transplant follow-up care—compels further investigation. Our findings help justify the development and testing of CIM-based interventions for HTx recipients. In addition, future research should explore what degree of CIM and which aspects of CIM are most relevant in view of achieving better outcomes in transplantation. Degree of CIM needs to be regarded as a valuable system-level factor that expresses the extent to which Tx centers have adopted principles of chronic illness care.

Acknowledgements

We would like to thank all the patients and clinicians who shared their time and effort in participating in our study.

Contributorship

SDG, FD, CR, and LB researched literature and conceived the primary study. MIC and KD were involved in data analysis. MIC wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Each BRIGHT study HTx center obtained ethical approval from their institutional review board and/or national ethics committee.

Funding

This study is funded by research grants of the International Transplant Nurses Society in 2008, the International Society for Heart and Lung Transplantation (ISHLT) in 2012, the Swiss Academy of Medical Sciences (SAMW) in 2013 as well as by an unrestricted research grant from Astellas Pharma. None of the organizations that provided funding has access to the data nor were involved in the preparation of the manuscript.

Guarantor

SDG

Informed consent

Written informed consent were obtained from the participating HTx recipients for their anonymized and aggregated information to be published in this article.

ORCID iDs

Maan Isabella Cajita https://orcid.org/0000-0002-2331-1229
Jan Van Keer https://orcid.org/0000-0003-4490-5170

References

1. Rosenberger EM, Fox KR, DiMartini AF, et al. Psychosocial factors and quality-of-life after
heart transplantation and mechanical circulatory support. Curr Opin Organ Transplant 2012; 17: 558–563.

2. Costanzo MR, Dipchand A, Starling R, et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914–956.

3. Farmer SA, Grady KL, Wang E, et al. Demographic, psychosocial, and behavioral factors associated with survival after heart transplantation. Ann Thorac Surg 2013; 95: 876–883.

4. De Geest S, Dobbels F, Gordon E, et al. Chronic illness management as an innovative pathway for enhancing long-term survival in transplantation. Am J Transplant 2011; 11: 2264–2265.

5. Lodhi SA, Lamb KE, and Meier-Kriesche HU. Improving long-term outcomes for transplant patients: making the case for long-term disease-specific and multidisciplinary research. Am J Transplant 2011; 11: 2262–2263.

6. Nuno R, Coleman K, Bengoa R, et al. Integrated care for chronic conditions: the contribution of the ICCC framework. Health Policy 2012; 105: 55–64.

7. World Health Organization. Innovative care for chronic conditions: building blocks for action. Global report. Geneva: WHO Press - World Health Organization, 2002.

8. Goodwin N. Understanding integrated care. Int J Integr Care 2016; 16: 6.

9. de Bruin SR, Versnel N, Lemmens LC, et al. Comprehensive care programs for patients with multiple chronic conditions: a systematic literature review. Health Policy 2012; 107: 108–145.

10. Cajita MI, Baumgartner E, Berben L, et al. Heart transplant centers with multidisciplinary team show a higher level of chronic illness management - findings from the international BRIGHT study. Heart Lung 2017; 46: 351–356.

11. Denhaerynck K, Berben L, Dobbels F, et al. Multilevel factors are associated with immunosuppressant nonadherence in heart transplant recipients: the international BRIGHT study. Am J Transplant 2018; 18: 1447–1460.

12. Berben L, Denhaerynck K, Dobbels F, et al. Building research initiative group: chronic illness management and adherence in transplantation (BRIGHT) study: study protocol. J Adv Nurs 2015; 71: 642–654.

13. De Geest S. (2012, May 31 - 2019, January 25). Building research initiative group: chronic illness management and adherence in transplantation (BRIGHT). Identifier NCT01608477. https://clinicaltrials.gov/show/NCT01608477.

14. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report–2011. J Heart Lung Transplant 2011; 30: 1078–1094.

15. Gugiu PC, Coryn C, Clark R, et al. Development and evaluation of the short version of the patient assessment of chronic illness care instrument. Chronic Illn 2009; 5: 268–276.

16. Iglesias K, Burnand B, and Peytreman-Briveaux I. PACIC instrument: disentangling dimensions using published validation models. Int J Qual Health Care 2014; 26: 250–260.

17. Berben L, Russell CL, Engberg S, et al. Development, content validity and inter-rater reliability testing of the chronic illness management implementation – building research initiative group: chronic illness management and adherence in transplantation: an instrument to assess the level of chronic illness management implemented in solid organ transplant programmes. Int J Care Coord 2014; 17: 59–71.

18. Dobbels F, Berben L, De Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation 2010; 90: 205–219.

19. Marsicano E, Fernandes N, Colugnati F, et al. Transcultural adaptation and initial validation of Brazilian-Portuguese version of the Basel assessment of adherence to immunosuppressive medications scale (BAASIS) in kidney transplants. BMC Nephrol 2013; 14: 108.

20. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73: 691–705.

21. De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med 2018; 169: 30–35.

22. Marshall AL, Smith BJ, Baumman AE, et al. Reliability and validity of a brief physical
activity assessment for use by family doctors. *Br J Sports Med* 2005; 39: 294–297. discussion 294-297.

23. Masyn KE. Latent class analysis and finite mixture modeling. In: Little TD (eds) *The oxford handbook of quantitative methods*. New York: Oxford University Press, 2013, pp.551–610.

24. Latent profile model, https://www.stata.com/manuals/semexample52g.pdf (n.d., accessed 8/29/2019).

25. Khush KK, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. *J Heart Lung Transplant* 2019; 38: 1056–1066.

26. Greene J, Hibbard JH, Sacks R, et al. When patient activation levels change, health outcomes and costs change, too. *Health Aff (Millwood)* 2015; 34: 431–437.

27. Nafradi L, Nakamoto K, and Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. *PLoS One* 2017; 12: e0186458.

28. Bissonnette J, Woodend K, Davies B, et al. Evaluation of a collaborative chronic care approach to improve outcomes in kidney transplant recipients. *Clin Transplant* 2013; 27: 232–238.

29. Schmid A, Hils S, Bogatyreva L, et al. Telemedically-supported case management of living-donor renal transplant recipients to optimize routine evidence-based aftercare: a single-center randomized controlled trial. *Am J Transplant* 2017; 17: 1594–1605.

30. Serper M and Asrani SK. Liver transplantation and chronic disease management: moving beyond patient and graft survival. *Am J Transplant* 2019.

31. Bauer MS, Damschroder L, Hagedorn H, et al. An introduction to implementation science for the non-specialist. *BMC Psychol* 2015; 3: 32.

32. De Geest S, Leppla L, Teynor A, et al. SMIle, https://nursing.unibas.ch/de/forschungsprojekte/forschung/forschung/smile/.